Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 6/20 | 0.64 |
| ▸ | ADH1B | P00325 | 4/20 | 0.64 |
| ▸ | ADH1C | P00326 | 5/20 | 0.52 |
| ▸ | ADH7 | P40394 | 2/20 | 0.52 |
| ▸ | ADH4 | P08319 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997344 | 0.80 | ADH1B (1.00) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL115609 | 0.80 | — | — | |
| SCHEMBL19658308 | 0.80 | ADH1B (1.00) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL27343431 | 0.79 | ADH1B (0.46) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL27417216 | 0.77 | IRAK4 (0.35) | ADH1AADH1BIRAK4 | |
| Hydrochloric Acid SCHEMBL4095046 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL9205102 | 0.77 | — | — | |
| SCHEMBL4917512 | 0.77 | ADH1A (0.58) | ADH1AADH1BADH1CADH7ADH4 | |
| Dimethylcarbate SCHEMBL11114306 | 0.76 | ADH1B (0.61) | ADH1AADH1BADH1CADH7ADH4 | |
| SCHEMBL21088347 | 0.75 | ADH1B (0.88) | ADH1AADH1BADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | claimed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | ADH1A 3780/4885ADH1B 4400/4885ADH1C 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.